Diligent Investors Reduces AbbVie Stake by 69.6%

Hedge fund sells over 5,800 shares of pharmaceutical giant in Q3

Mar. 14, 2026 at 8:38am

Got story updates? Submit your updates here. ›

Diligent Investors LLC, a hedge fund, reduced its position in AbbVie Inc. (NYSE: ABBV) by 69.6% during the third quarter, according to a recent 13F filing. The fund now owns 2,557 shares of the pharmaceutical company's stock, down from 8,414 shares previously.

Why it matters

AbbVie is a major player in the pharmaceutical industry, known for blockbuster drugs like Humira. Tracking changes in institutional ownership, like this reduction by Diligent Investors, can provide insights into market sentiment around the company.

The details

In its 13F filing, Diligent Investors reported selling 5,857 shares of AbbVie during the third quarter. The fund now holds 2,557 shares of the company, valued at $592,000 at the end of the reporting period.

  • Diligent Investors reduced its AbbVie position during the 3rd quarter of 2026.

The players

Diligent Investors LLC

A hedge fund that previously held a position in pharmaceutical company AbbVie Inc.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This reduction in ownership by Diligent Investors could signal a shift in sentiment around AbbVie, though more data would be needed to draw broader conclusions. Investors will likely continue to monitor institutional activity around the stock as an indicator of market trends.